Αρχική World News FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour World News FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour Από Ogkologos - 4 Απριλίου, 2025 927 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR England moves to a single-dose HPV vaccine 21 Ιουνίου, 2023 EMA Recommends Extension of Therapeutic Indications for Serplulimab 31 Ιουλίου, 2026 The Cancer Moonshot: A Midpoint Progress Update 11 Ιανουαρίου, 2021 MGUS to Myeloma: Study Suggests Risk of Progression Can Change 13 Αυγούστου, 2019 Φόρτωση περισσοτέρων HOT NEWS Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... Women at High Risk of Breast Cancer Find it Hard to... Discovering the BRCA2 gene – 25 years on Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in...